Involuntary MDMB-4en-PINACA intoxications following cannabis consumption: clinical and analytical findings
R. Goncalves, M. Labadie, Simon Chouraqui, A. Peyré, N. Castaing, A. Daveluy, M. Molimard
Clinical toxicology December 1, 2021 DOI: 10.1080/15563650.2021.1994144 via Semantic Scholar
Summary
AI-generated from the abstractA synthetic cannabinoid called MDMB-4en-PINACA, found in low-THC cannabis products, caused severe intoxication in 13 patients between November 2020 and March 2021. All patients had altered mental status; other symptoms included seizures (5 cases), vomiting (6), paranoia (6), hallucinations (3), and headaches (3). Patients typically recovered to normal or near-normal after about 11 hours of observation. No deaths occurred. Toxicological analysis confirmed MDMB-4en-PINACA in urine, blood, or drug material samples from all patients, indicating the substance can cause or contribute to various clinical disorders.
Study at a glance
| Characteristics | Observational cohort Peer reviewed |
|---|---|
| Sample size | 13 |
| Population | Patients with unexpected or unusually severe effects and Poisoning Severity Score ≥2 after cannabis consumption |
| Duration | Approximately 11 hours of observation |
| Keywords | Medicine |
| Key finding | MDMB-4en-PINACA, a synthetic cannabinoid receptor agonist, can cause severe intoxication including altered mental status, seizures, and psychiatric symptoms in cannabis consumers. |
Abstract
Abstract Background and aims MDMB-4en-PINACA is a synthetic cannabinoid receptor agonist (SCRA) that has recently emerged. Data regarding clinical presentations in the event of intoxication is scarce. This study presents MDMB-4en-PINACA identification in cannabis consumers with clinical and analytical descriptions. Methods Between November 2020 and March 2021, all patients with unexpected or unusually severe effects and Poisoning Severity Score (PSS) greater than or equal to 2 after cannabis consumption were included. Blood and/or urine samples were collected for toxicological analysis. When available, drug material samples were also collected for analysis. Results Between November 2020 and March 2021, 13 patients were included. All cases typically presented with altered mental status (n = 13), and nearly all had returned to a normal or quasi-normal state after around 11 h of observation. Neurological symptoms included headaches (n = 3), hallucinations (3), mydriasis (3), amnesia (2) and seizures (5). Psychiatric symptoms were paranoia (6) and anxiety (2). Digestive symptoms were nausea (2) and vomiting (6). No deaths were recorded. All patients were positive for the SCRA MDMB-4en-PINACA in urine, blood and/or drug material sample. Results from toxicology testing paired with case history showed the potential for MDMB-4en-PINACA to cause or contribute to different clinical disorders. Conclusions This study highlights the risk of intoxication by SCRAs when taking low-THC cannabis products. Forensic scientists, public health and public safety officials, law enforcement personnel and clinicians should be aware of the impact that these emergent SCRAs may have in their work, especially MDMB-4en-PINACA.